Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

Wang Baiyan; Liu Jie; Chen Yin-Xia; Cao Xing-Mei; Zhao Wan-Hong; Wang Jian-Li; Ma Xiao-Rong; Yang Yun; Zhang Peng-Yu; Wang Fang-Xia; Gu Liu-Fang; Lei Bo; Wang Jin; Bai Ju; Zhang Yi-Lin; Xu Yan; He Ai-Li; Zhang Wang-Gang

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

【24h】

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

机译：吉西他滨联合环磷酰胺，长调温和泼尼松氢化特征的疗效和不良反应在复发和/或难治性非霍奇金淋巴瘤中

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Wang Baiyan; Liu Jie; Chen Yin-Xia; Cao Xing-Mei; Zhao Wan-Hong; Wang Jian-Li; Ma Xiao-Rong; Yang Yun; Zhang Peng-Yu; Wang Fang-Xia; Gu Liu-Fang; Lei Bo; Wang Jin; Bai Ju; Zhang Yi-Lin; Xu Yan; He Ai-Li; Zhang Wang-Gang;
展开▼
作者单位

Xi An Jiao Tong Univ Affiliated Hosp 2 Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Toronto ON Canada;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

Xi An Jiao Tong Univ Affiliated Hosp 2 Dept Hematol Xian Shaanxi Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma [J] . Wang Baiyan, Liu Jie, Chen Yin-Xia, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：吉西他滨联合环磷酰胺，长调温和泼尼松氢化特征的疗效和不良反应在复发和/或难治性非霍奇金淋巴瘤中
2. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma. [J] . Gerecitano J, Portlock C, Hamlin P, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第8期

机译：每周一次和每周两次硼替佐米联合利妥昔单抗，环磷酰胺和泼尼松在复发或难治性非霍奇金淋巴瘤中进行的I期试验。
3. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. [J] . Di Renzo N, Brugiatelli M, Montanini A, Leukemia and lymphoma . 2006,第3期

机译：长春瑞滨，吉西他滨，丙卡巴肼和泼尼松（ViGePP）作为复发性或难治性侵袭性非霍奇金淋巴瘤（NHL）的挽救疗法：Gruppo Italiano进行的II期研究结果。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab Cyclophosphamide and Prednisone in Relapsed or Refractory non-Hodgkin Lymphoma [O] . John Gerecitano, Carol Portlock, Paul Hamlin, -1

机译：每周的I期临床试验并每周两次用硼替佐米利妥昔单抗环磷酰胺和强的松在复发或难治性非霍奇金淋巴瘤
6. THE EFFICACY AND TOLERANCE OF CHIDAMIDE, PREDNISONE, CYCLOPHOSPHAMIDE AND THALIDOMIDE (C-PCT) IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A PILOT STUDY [O] . W. Xu, H. Zhu, L. Wang, 2017

机译：赤酰胺，泼尼松，环磷酰胺和沙利度胺（C-PCT）在复发或难治外周T细胞淋巴瘤的疗效和耐受性：试验研究

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

著录项

相似文献

相关主题

期刊订阅